ALK inhibitors in the treatment of advanced NSCLC.

Pharmacologic agents that target protein products of oncogenes in tumors are playing an increasing clinical role in the treatment of cancer. Currently, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the standard of care for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations. Subsequently other genetic abnormalities with "driver" characteristics - implying transforming and tumor maintenance capabilities have been extensively reported in several small distinct subsets of NSCLC. Among these rare genetic changes, anaplastic lymphoma kinase (ALK) gene rearrangements, most often consisting in a chromosome 2 inversion leading to a fusion with the echinoderm microtubule-associated protein like 4 (EML4) gene, results in the abnormal expression and activation of this tyrosine kinase in the cytoplasm of cancer cells. This rearrangement occurs in 2-5% of NSCLC, predominantly in young (50 years or younger), never- or former-smokers with adenocarcinoma. This aberration most commonly occurs a independently of EGFR and KRAS gene mutations. A fluorescent in situ hybridization assay was approved by the US Food and Drug Administration (FDA) as the standard method for the detection of ALK gene rearrangement in clinical practice and is considered the gold standard. Crizotinib, a first-in-class dual ALK and c-MET inhibitor, has been shown to be particularly effective against ALK positive NSCLC, showing dramatic and prolonged responses with low toxicity, predominantly restricted to the gastro-intestinal and visual systems, and generally self-limiting or easily managed. However, resistance to crizotinib inevitably emerges. The molecular mechanisms of resistance are currently under investigation, as are therapeutic approaches including crizotinib-based combination therapy and novel agents such as Hsp90 inhibitors. This review aims to present the current knowledge on this fusion gene, the clinic-pathological profile of ALK rearranged NSCLC, and to review the existing literature on ALK inhibitors, focusing on their role in the treatment of NSCLC.

Gridelli C ，Peters S ，Sgambato A ，Casaluce F ，Adjei AA ，Ciardiello F ... -  《-》

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.

Casaluce F ，Sgambato A ，Sacco PC ，Palazzolo G ，Maione P ，Rossi A ，Ciardiello F ，Gridelli C ... -  《-》

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Casaluce F ，Sgambato A ，Maione P ，Rossi A ，Ferrara C ，Napolitano A ，Palazzolo G ，Ciardiello F ，Gridelli C ... -  《-》

HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.

Fang DD ，Zhang B ，Gu Q ，Lira M ，Xu Q ，Sun H ，Qian M ，Sheng W ，Ozeck M ，Wang Z ，Zhang C ，Chen X ，Chen KX ，Li J ，Chen SH ，Christensen J ，Mao M ，Chan CC ... -  《-》

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.

Ou SH 《Drug Design Development and Therapy》